Skip to main content

Anti-Rheumatic Rx

STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months. https://t.co/HLLhwgcVrS https://t.co/MKpeXhVdoe
Dr. John Cush @RheumNow( View Tweet )

GLP-1 drugs cost-effective for knee osteoarthritis and obesity

EurekAlert!

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at

Read Article
Study of 43 PsA pts starting bDMARD shows Calprotectin was elevated in PsA, decreased w/ biologics, but had no signif correlation w/ US synovitis. Baseline calprotectin, S100A12, IL-6, IL-17A, IL-23, CXCL10 were high. Calprotectin, S100A12, IL-6 decreased w/ Rx (p < 0.05).

Dr. John Cush @RheumNow( View Tweet )

GCs have potent anti-inflammatory effects but it’s long term complications can be catastrophic. In SLE pts, it shows a 3-fold increased risk of organ damage for each addtl 1mg of Pred/day. 📌Aim for short duration of use with lowest effective dose @RheumNow #APLAR25 https://t.co/UugrcX073Z

Equal Safety of JAK Inhibitors and TNF Inhibitors

JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for the treatment of immune-

Read Article
Target trial emulation looked at CV (MACE) events in 18,120 propensity score–matched adults with gout starting allopurinol who were given NSAIDs or colchicine for prophylaxis. MACE & CV death were signif. higher w/ NSAIDs vs Colchicine (HRs of 1.56 and 2.50), respectively. https://t.co/0T8slmPBng
Dr. John Cush @RheumNow( View Tweet )
SMART study - Single vs. Split Dose Methotrexate in RA Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients. https://t.co/JN5wPGNjao https://t.co/lizsrtVHwf
Dr. John Cush @RheumNow( View Tweet )

STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia

Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months. 

The fate of Individuals elevated anti-cyclic citrullinated peptide (anti-CCP) antibodies and

Read Article
Different B cells depletion strategies in SARDs highlighted by Georg Schett From low and short lived depletion achieved w/ drugs to sustained deep tissular depletion with CAR T cells leading to potential immune reset @RheumNow #APLAR25 https://t.co/t35lrzEomF
Aurelie Najm @AurelieRheumo( View Tweet )
STOP-RA results published in A&R. 144 at risk, CCP+ pts were enrolled to received HCQ vs PBO for 12 mos, w/ 24 mos F/U. Progression to RA seen in 30.4% on HCQ vs 32.9% on PBO (NS; P=0.52). Also IA, Jt Sxs, severity & adverse events were similar between groups.

Dr. John Cush @RheumNow( View Tweet )

AbbVie's US patent protection for Rinvoq (upadacitinib) will run till April 2037. SEC filing shows AbbVie has reached an agreement with generic manufacturers challenging Rinvoq patents. UPA is their 2nd leading product with nearly $3.75 billion worldwide sales in 1st 1/2 of

Dr. John Cush @RheumNow( View Tweet )

Hitting the Target: T2T Therapy in SLE

Treat-to-target strategies are not a new concept in rheumatology. It has shown to improve patient outcomes and quality of life in RA and PsA, and is now being increasingly adopted not only in SLE research but also in clinical practice. This article reviews key highlights from Dr. Eric Morand’s

Read Article
Antifibrotics - A New Class of Therapies in Rheumatology? Rheumatologists typically manage systemic autoimmune rheumatic diseases (SARD) and associated interstitial lung disease (ILD) with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic https://t.co/IobQagC0ZE
Dr. John Cush @RheumNow( View Tweet )

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are there benefits to diet or vegan diets? What's the effect of menopause on CTD?  Ro52 makes a big entrance with all our ILD coverage this month.

Read Article

SMART study - Single vs. Split Dose Methotrexate in RA

Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients.

Read Article
Regional Disparities in DMARD Management for RA Treatment Dr. Aurelie Najm, Glasgow, reports on a session on "Updates on DMARDs treatment: global standards and regional adaptations" from the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/zDo5NxKtbE https://t.co/kF9FxyWkIQ
Dr. John Cush @RheumNow( View Tweet )
COLCHICORT Trial The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors. https://t.co/CC2yVRXbD5 https://t.co/ebLa3FUbGR
Dr. John Cush @RheumNow( View Tweet )
This slide reflects the rheumatologist’s goals for treating #lupus Prof. Mosca also highlights the fact that achieving targets is as important as maintaining these treatment targets. @RheumNow #APLAR25 https://t.co/u8fw3fThXI
Optimizing outcomes of pregnancy in #lupus: 📌 all patients should undergo preconception counselling 📌 close monitoring by a multidisciplinary team - a ⬇️ cerebroplacental ratio reflects placental dysfunction #APLAR25 @RheumNow @rheumarhyme https://t.co/RSyqgpRTG5
Study of 111 TAKayasu arteritis pts Rx w/ 74 MMF+MTX vs 37 CYC/AZA. Response rates at 28 & 52 weeks were 58.1% and 55.4% in the MMF+MTX group, respectively, higher than 32.4% at both time points in the CYC/AZA group. https://t.co/wqlOLH0VEA https://t.co/nbLvcyYkbn
Dr. John Cush @RheumNow( View Tweet )

ERS/EULAR guidelines for CTD-related interstitial lung disease

The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have published clinical practice guidelines for the evaluation and management of connective tissue diseases (CTD) associated interstitial lung disease (ILD) in two simultaneous publications in

Read Article

COLCHICORT Trial

The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors.

Read Article
Prof Takeuchi on DMARDs treatment and regional disparities For similar dose, serum concentration of the polyglutamate (active) form of MTX is much higher in Japanese than US patients And also high levels achieved much quicker in Japanese than US patients This is strong https://t.co/ikp63wWifj
Aurelie Najm @AurelieRheumo( View Tweet )
Abatacept and Methotrexate may Lower Risk of Interstitial Lung Disease in RA A post hoc, pooled analysis of of rheumatoid arthritis (RA) clinical trials shows those received abatacept had a lower rate of Interstitial lung disease (ILD). https://t.co/3AISriCUeC https://t.co/nN03e4ZBDU
Dr. John Cush @RheumNow( View Tweet )
One of the most impt updates recommended to add a bDMARD if tx target is not achieved by the 1st csDMARD (no more prognostic stratification) But, accdg to Dr. Smolen, adding a 2nd csDMARD should still be considered especially in resource-limited countries. @RheumNow #APLAR25 https://t.co/ZQiviGcrYp
×